This data strongly suggests that the primary tumor growth inhibition and subsequent durable tumor control and improved survival in MOC1 tumor bearing mice following rapamycin treatment is due to preserved CD8 T-cell responses, whereas the lack of such responses following PD901 treatment is due to MEK-induced inhibition of adaptive immunity. This evidence concerns the gene CD8A and neoplasm.